SHENZEN, China, June 1 /PRNewswire-FirstCall/ - Hard to Treat
Diseases, Inc. (HTDS; http://www.htdsmedical.com) and Shenzhen
Mellow Hope (www.mellowhope.com) announce, that the company
commenced clinical trials for the company's Hepatitis A (brand name
MEVAC-A) vaccine.
Following 2 years of cooperation with the Vietnamese Ministry of
Health, HTDS reached the stage of clinical trials for its MEVAC-A.
To complete the trials, the company obtained the Import License for
the samples, and expects to ship those to Vietnam in June
2010.
The company expects to finalize the clinical trials within 6
months. Following the trials, Vietnamese Ministry of Health will
release Registration Certificate for the vaccine immediately and
the company will start to market its product on this growing market
(Domestic growth shown 7% increase from 2000 to 2005).
A source close to the company stated, "The past two years we
worked closely with the Vietnamese authorities and now is the time
for us to finish and reap the results. We expect to gain a solid
spot on the Vietnamese vaccine market. With the Vietnam's population of over 85 million, we
expect to ship large quantities of our product to the country and
bring solid profits to HTDS and its shareholders."
The company reminds its shareholders and followers to monitor
PinkSheets.com Filing section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk. In this regard, Mina Mar
Group works diligently to answer and address all the pressing
issues regarding its clients to the shareholders' satisfaction. MMG
is in constant contact with the companies, addressing, obtaining
and processing all inquiries. MMG is often one of the advisors or
IR companies utilized by the issuer. Depending on the location of
the issuer and management's availability, it may take up to several
days to address any pressing issues. In a normal course of business
and a pending transaction, the issuer may opt to remain silent in
order not to lose advantage to a competitor. MMG is mindful that
sometimes shareholders want answers immediately, which for the
above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The
company is mindful that short sellers, the company competitors and
stock bashers stalk small cap Pink Sheets listed companies with
hidden agendas. Visit http://www.stockbasher.com/ and find out what
criminal and civil actions the US authorities are taking against
web sites and the remedies available to you as an individual
investor. Discover for yourself why and how USA based small businesses and the backbone of
the economy suffer. Stay informed and do not allow entrepreneurs
dreams, innovations, and their access to capital to be thwarted as
"scalpers" and day traders vigorously day in and day out try to
exploit and extinguish US innovation and progress for quick
profits.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about
future expectations, plans, prospects or performance of Hard to
Treat Diseases, Inc. that constitute forward-looking statements for
purposes of the Safe Harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be",
"expects", "may affect", "believed", "estimate", "project" and
similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases, Inc. cautions
you that any forward-looking information provided by or on behalf
of Hard to Treat Diseases, Inc. is not a guarantee of future
performance. None of the information in this press release
constitutes or is intended as an offer to sell securities or
investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important
factors, some of which are beyond Hard to Treat Diseases, Inc.'s
control. In addition to those discussed in Hard to Treat Diseases,
Inc.'s press releases, public filings, and statements by Hard to
Treat Diseases, Inc.'s management, including, but not limited to,
Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its
existing capital resources, Hard to Treat Diseases, Inc.'s ability
to raise additional capital to fund future operations, Hard to
Treat Diseases, Inc.'s ability to repay its existing indebtedness,
the uncertainties involved in estimating market opportunities, and
in identifying contracts which match Hard to Treat Diseases, Inc.'s
capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements
were made. Hard to Treat Diseases, Inc. does not undertake any
obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated
events.
CONTACT: For any investor relations matters, please contact
www.minamargroup.net/helpdesk; Investor Relations Department
Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate
Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases
